Talk:Solriamfetol

Accuracy Updates
I am an employee of Jazz Pharmaceuticals plc (Jazz), and my intent is to correct misinformation related to Jazz products or related disease states in a truthful and non-misleading manner.

All proposed edits will be requested through the Talk Page function of the site, in accordance with FDA’s draft Guidance, “Internet/Social Media Platforms: Correcting Independent Third-Party Misinformation About Prescription Drugs and Medical Devices”. I will disclose my employment at Jazz with each requested edit made through the Talk page. All of the edits that I request are made with the knowledge and approval of Jazz.

To report any potential negative side effects for Jazz products, please contact Jazz Pharmaceuticals at 1-800-520-5568. You are also encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch, or call 1-800-FDA-1088.

I suggest making edits to the lead section in order to reflect correct information regarding the treatments JZP-110 is currently under development for.
 * I am reworking this stub based on better sources. In general please bring independent sources and please make sure every change you suggest that is WP:Biomedical information is supported by appropriate sources per WP:MEDRS.  Jytdog (talk) 13:44, 15 April 2018 (UTC)

(please delete text from "Solriamfetol (developmental code names" through "hypersomnia, and renal failure" and replace with the following text): Solriamfetol (developmental code names JZP-110, ADX-N05, YKP 10A, others) is a norepinephrine-dopamine reuptake inhibitor (DNRI) in development for treatment of excessive sleepiness in adult patients with narcolepsy, OSA, and Parkinson's disease.

--CPark 2017 (talk) 15:24, 13 April 2018 (UTC)
 * declined. See above.Jytdog (talk) 13:44, 15 April 2018 (UTC)

It is a low-potency (please change NDRI to DNRI), with respective IC50 values for the dopamine and norepinephrine transporters of 2.9 and 4.4 μM, and shows a low abuse liability. --CPark 2017 (talk) 15:24, 13 April 2018 (UTC)
 * declined. See above.Jytdog (talk) 13:44, 15 April 2018 (UTC)

(please delete text from "As of July 2017, through renal failure) and replace with the following text): In 2014, Jazz Pharmaceuticals acquired a license to develop and commercialize solriamfetol from Aerial Biopharma. Jazz Pharmaceuticals has worldwide development, manufacturing, and commercialization rights to solriamfetol, excluding certain jurisdictions in Asia. SK Biopharmaceuticals, the discoverer of the compound (also known as SKL-N05), maintains rights in 12 Asian markets, including Korea, China and Japan. Solriamfetol has orphan drug designation in the United States for narcolepsy.

CPark 2017 (talk) 15:24, 13 April 2018 (UTC)
 * declined. See above.Jytdog (talk) 13:44, 15 April 2018 (UTC)